The Tectonic Therapeutic, Inc. (NASDAQ: TECX) SEC filings page brings together the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tectonic is a clinical-stage biotechnology company focused on GPCR-targeted biologic medicines, and its filings provide structured insight into financial results, clinical development updates and corporate events.
Investors can use this page to access Form 10‑Q and Form 10‑K reports, which contain detailed discussions of Tectonic’s research and development activities, risk factors, and financial statements. For a company advancing programs such as TX45 in Group 2 pulmonary hypertension and PH‑ILD, and TX2100 for Hereditary Hemorrhagic Telangiectasia, these periodic reports explain how clinical trial progress and pipeline strategy relate to operating expenses and liquidity.
The page also surfaces Form 8‑K current reports, where Tectonic discloses material events such as quarterly financial results, positive topline clinical data, updated corporate presentations, and other significant announcements. These filings often reference attached press releases and slide decks that elaborate on trial designs, endpoints, and topline outcomes.
In addition, users can review Section 16 filings such as Form 4, which report changes in beneficial ownership by directors, officers, and other insiders, as well as proxy materials that discuss governance and executive compensation. Stock Titan’s platform layers AI-powered summaries on top of these documents to highlight key points, explain technical language, and help readers quickly understand the implications of lengthy filings without replacing the underlying source documents.
Together, the TECX SEC filings and AI summaries give a structured view of how Tectonic communicates its financial condition, clinical-stage risks, and strategic focus on GPCR-targeted biologics to regulators and investors.
Marcella K. Ruddy, Chief Medical Officer of Tectonic Therapeutic, Inc. (TECX), received equity awards on 09/25/2025. The filing shows a grant of 5,370 restricted stock units (each convertible to one share) that vest in three equal annual installments on 09/25/2026, 09/25/2027 and 09/25/2028, subject to continued service. An employee stock option with a $14.71 exercise price covering 9,750 shares was also granted on 09/25/2025; those options vest in 48 equal monthly installments beginning 10/25/2025 and expire 09/24/2035. After these transactions, Ms. Ruddy beneficially owns 55,311 shares. The Form 4 is signed by an attorney-in-fact on 09/29/2025.
Tectonic Therapeutic CEO and director Reicin Alise reported multiple equity awards and holdings on Form 4. The filing shows acquisition on 09/25/2025 of 14,700 restricted stock units (RSUs) that vest in three equal annual installments on 09/25/2026, 09/25/2027 and 09/25/2028, subject to continued service. The reporting person also holds an employee stock option to buy 26,710 shares at $14.71 per share exercisable beginning 09/25/2025 with expiration 09/24/2035; the option vests monthly over 48 installments starting 10/25/2025.
The report discloses 228,185 shares beneficially owned directly after the RSU acquisition and 124,530 shares held indirectly by the Reicin-Boiarsky Family Trust, where the reporting person may share voting and dispositive power but disclaims beneficial ownership except to extent of pecuniary interest.
Tectonic Therapeutic, Inc. (TECX) – Form 4 filing overview
CEO and Director Alise Reicin reported a single administrative transaction dated 06/20/2025. The filing shows 859 common shares disposed (Code F) at a price of $19.81 per share. The shares were withheld by the issuer exclusively to cover tax obligations triggered by the vesting and settlement of restricted stock units granted on 12/04/2024. No open-market purchase or sale occurred.
After the transaction, Reicin’s beneficial ownership stands at 213,485 shares held directly and 124,530 shares held indirectly through the Reicin-Boiarsky Family Trust, where her spouse is co-trustee. No derivative securities were exercised, acquired, or disposed of, and there are no new option grants or expirations disclosed.
The reported disposal represents less than 0.3% of Reicin’s total reported holdings, indicating a routine, non-material adjustment rather than a directional change in insider sentiment.